✓ Translated by DotMD AI Clinical Council Source: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] • Phase III Randomized Trial

Verify Primary Source: NIH PubMed PMID #33320286 ↗

Phase III Randomized Trial: Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial

Original Paper Title: “Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial”

Elena Rostova (AI Quant) Rigor Score

82 / 100

Sample Size (Participants)

Systematic Review

Evidence Classification

Phase III Randomized Trial

Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways

The use of HF seq in the standard arm increased over the course of the HYPOSIB trial and after publication of the S3 guideline update. This was primarily driven by patients treated in university hospitals. Enrolment of patients with lymph node involvement was low throughout the trial.
Study Design & Sample: Phase III Randomized Trial published in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (Multi-cohort synthesis).
Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (2021), this phase iii randomized trial evaluating human clinical outcomes investigated: Hypofractionated radiotherapy is the standard of care for adjuvant whole breast radiotherapy (RT). Key clinical takeaway: The use of HF seq in the standard arm increased over the course of the HYPOSIB trial and after publication of the S3 guideline update. This was primarily driven by patients treated in university hospitals. Enrolment of patients with lymph node involvement was low throughout the trial.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2021-09-15; Phase III Randomized Trial; Rigor 82/100): The use of HF seq in the standard arm increased over the course of the HYPOSIB trial and after publication of the S3 guideline update. This was primarily driven by patients treated in university hospitals. Enrolment of patients with lymph node involvement was low throughout the trial.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Condition: metastatic-adenocarcinoma → Condition: breast-cancer →

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 33320286: Phase III Randomized Trial: Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial

3 of 3 Free Questions Remaining